Therapeutic use of PDZ protein-protein interaction antagonism

Area of Science:

• Molecular Biology
• Pharmacology
• Biochemistry

Background:

• PDZ domains are crucial intracellular interaction modules involved in numerous cellular pathways.
• Aberrant activation of these pathways is linked to diseases, notably various cancers.
• PDZ domains recognize the C-termini of target proteins like G protein-coupled receptors and ion channels.

Purpose of the Study:

• To review recent advancements in the development of small-molecule inhibitors targeting PDZ domains.
• To explore the potential of modulating PDZ-involved interactions for therapeutic applications.
• To focus on postsynaptic density 95 (PSD-95) and dishevelled (Dvl) as key PDZ domain-containing targets.

Main Methods:

• Literature review of recent progress in small-molecule PDZ inhibitor development.
• Analysis of PDZ domain function in intracellular signaling pathways.
• Focus on specific PDZ domain-containing proteins: PSD-95 and Dvl.

Main Results:

• Small-molecule inhibitors targeting PDZ domains are a developing area in drug discovery.
• These inhibitors hold potential for dissecting molecular mechanisms and creating pharmaceutical agents.
• Modulating PDZ interactions could target important drug targets like G protein-coupled receptors and ion channels.

Conclusions:

• Small-molecule PDZ inhibitors represent an attractive strategy for pharmaceutical development.
• Targeting PDZ domains offers a novel approach to modulate cellular signaling pathways implicated in disease.
• Further research into PDZ inhibitors, particularly those targeting PSD-95 and Dvl, is warranted.